Medical Condition News

RSS

Coeliac UK and Innovate UK announce £180k research funding

Coeliac UK, the UK charity for people who need to live gluten-free, along with Innovate UK, the UK’s innovation agency, have £180k available for research and are inviting applications from UK businesses and researchers.

6 Jun 2019

Study offers hope to slow down or prevent progression of Parkinson’s

Results from a study published today looking at a molecule targeting clumps of alpha-synuclein, a key protein linked to Parkinson’s, offers hope that it may be possible to slow down or prevent the progression of the condition in humans.

6 Jun 2019

New immunosuppressive regimens may improve outcomes for kidney transplant patients

Preliminary results from a $5.2 million clinical trial led by University of Cincinnati researchers show that the immunosuppressive drug belatacept can help safely and effectively treat kidney transplant patients without the negative long-term side effects of traditional immunosuppressive regimens, the study's leaders announced this week.

6 Jun 2019

Chemical changes in the brain may be associated with unexplained motor symptoms

A new study finds that people who have movement problems, symptoms that cannot be explained by an underlying disease, may have chemical changes in specific areas of the brain.

6 Jun 2019

Irregular sleep patterns associated with metabolic abnormalities

A new study has found that not sticking to a regular bedtime and wakeup schedule--and getting different amounts of sleep each night--can put a person at higher risk for obesity, high cholesterol, hypertension, high blood sugar and other metabolic disorders.

6 Jun 2019

Nanotechnology treatment reverses multiple sclerosis symptoms in mice

A nanotechnology treatment derived from bone marrow stem cells has reversed multiple sclerosis symptoms in mice and could eventually be used to help humans, according to a new study led by University of California, Irvine researchers.

6 Jun 2019

Obesity linked with greater symptomatic severity of multiple sclerosis

Obesity is an aggravating factor in relapsing-remitting multiple sclerosis, the most common form of the disease.

6 Jun 2019

High salt intake inhibits tumor growth in mice, shows study

A study by an international research team led by Professor Markus Kleinewietfeld shows that high salt intake inhibits tumor growth in mice.

6 Jun 2019

UA physician-scientist receives grant to study sleep apnea and heart health

Obstructive sleep apnea is a common condition that has been associated with increased mortality, especially in individuals who have cardiac arrhythmia. A University of Arizona physician-scientist has received a grant to try to find out why.

6 Jun 2019

Unsalted tomato juice may help reduce cardiovascular disease risk

In a study published in Food Science & Nutrition, drinking unsalted tomato juice lowered blood pressure and LDL cholesterol in Japanese adults at risk of cardiovascular disease.

6 Jun 2019

New study examines non‐medical use of anti-anxiety medication

There is concern about the misuse of the sedative anti-anxiety medication alprazolam (Xanax®) because of the "high" it can create.

6 Jun 2019

Alzheimer's therapy may be effective in treating individuals addicted to opioids

Clinical trial results reveal that a medication used to treat Alzheimer's disease may also be an effective therapy for individuals addicted to opioids. The findings are published in The American Journal on Addictions.

6 Jun 2019

Sleep extension may help reduce cardiometabolic risk

Increasing sleep duration may help reduce cardiometabolic risk--or the risk of heart disease and metabolic disorders-- in individuals who do not get enough sleep, according to an analysis of all published studies on the topic.

6 Jun 2019

Improve Patient Safety with Tie Layer

The Tielayer is a new ultra-thin thermoplastic coating that can transform the medical device industry. In this interview, Tara McCutchen, Global Market Manager for Zeus talks to AZoM about their new product the Tielayer and how it works in conjunction with the FEP 2:1.

From Zeus Inc. 5 Jun 2019